GENPREX, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Published: 2021-09-29 16:20:07 ET GNPX

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As disclosed in the Current Report on Form 8-K of Genprex, Inc. (the "Company") filed with the Securities and Exchange Commission on September 28, 2021, the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively. With these new appointments, Michael Redman, the Company's Executive Vice President and Chief Operating Officer is no longer overseeing the Company's clinical and manufacturing operations. The Company is in discussions with Mr. Redman to remain with the Company in an alternate role.

Item 9.01: Financial Statements and Exhibits.

--------------------------------------------------------------------------------